| P2093 | author name string | Stacey Culp | |
| | Olivier Nolan-Stevaux | |
| | Dineli Wickramasinghe | |
| | Wendy Zhong | |
| | Joseph Hoover | |
| | Astrid Ruefli-Brasse | |
| | Kathy Shaffer | |
| P2860 | cites work | Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex | Q24294521 |
| | Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells | Q24309588 |
| | Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells | Q24315838 |
| | Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis | Q24321895 |
| | Endoglin forms a heteromeric complex with the signaling receptors for transforming growth factor-beta | Q24336809 |
| | Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells | Q24337230 |
| | Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells | Q24337548 |
| | Bone morphogenetic protein-9 is a circulating vascular quiescence factor | Q24657942 |
| | Mural cell associated VEGF is required for organotypic vessel formation | Q27348757 |
| | Defective angiogenesis in mice lacking endoglin | Q28144833 |
| | Crystal structure of BMP-9 and functional interactions with pro-region and receptors | Q28246829 |
| | BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis | Q28289169 |
| | Loss of distinct arterial and venous boundaries in mice lacking endoglin, a vascular-specific TGFbeta coreceptor | Q28506951 |
| | Arteriovenous malformations in mice lacking activin receptor-like kinase-1 | Q28513355 |
| | A murine model of hereditary hemorrhagic telangiectasia | Q28592376 |
| | How cells read TGF-beta signals | Q29619993 |
| | Reduced tumor growth and angiogenesis in endoglin-haploinsufficient mice | Q33263752 |
| | ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth | Q34096297 |
| | Structural and functional insights into endoglin ligand recognition and binding. | Q34162465 |
| | ALK1 as an emerging target for antiangiogenic therapy of cancer | Q35127963 |
| | Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice | Q35157425 |
| | Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth | Q35314203 |
| | Endoglin promotes TGF-β/Smad1 signaling in scleroderma fibroblasts | Q36054237 |
| | A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer | Q36205086 |
| | Extracellular control of TGFbeta signalling in vascular development and disease | Q36951674 |
| | Endoglin-mediated vascular remodeling: mechanisms underlying hereditary hemorrhagic telangiectasia | Q37060998 |
| | Endoglin (CD105): a marker of tumor vasculature and potential target for therapy | Q37125562 |
| | Emerging role of bone morphogenetic proteins in angiogenesis | Q37510292 |
| | The emerging role of TGF-beta superfamily coreceptors in cancer. | Q37553118 |
| | Signaling by members of the TGF-beta family in vascular morphogenesis and disease | Q37775374 |
| | The physiological role of endoglin in the cardiovascular system. | Q37775427 |
| | Endoglin-Targeted Cancer Therapy | Q37804900 |
| | TGF-β receptor signaling pathways in angiogenesis; emerging targets for anti-angiogenesis therapy. | Q37880946 |
| | Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors | Q39646992 |
| | Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. | Q39753483 |
| | TGFbeta-stimulated Smad1/5 phosphorylation requires the ALK5 L45 loop and mediates the pro-migratory TGFbeta switch | Q39903519 |
| | Transforming growth factor beta-induced Smad1/5 phosphorylation in epithelial cells is mediated by novel receptor complexes and is essential for anchorage-independent growth | Q39939459 |
| | Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction | Q40251249 |
| | Expression analysis of four endoglin missense mutations suggests that haploinsufficiency is the predominant mechanism for hereditary hemorrhagic telangiectasia type 1. | Q40920042 |
| | Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting | Q41964822 |
| | Structural model of human endoglin, a transmembrane receptor responsible for hereditary hemorrhagic telangiectasia. | Q42602490 |
| | BMP9 is produced by hepatocytes and circulates mainly in an active mature form complexed to its prodomain. | Q42808856 |
| | Transforming Growth Factor {beta} Can Stimulate Smad1 Phosphorylation Independently of Bone Morphogenic Protein Receptors | Q43150619 |
| | Matrix GLA protein stimulates VEGF expression through increased transforming growth factor-beta1 activity in endothelial cells | Q46172310 |
| | Blood outgrowth endothelial cells from Hereditary Haemorrhagic Telangiectasia patients reveal abnormalities compatible with vascular lesions | Q46580161 |
| | Transforming growth factor-beta1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer | Q77555131 |
| | An in vitro model of angiogenesis: basic features | Q79097258 |
| | Endoglin structure and function: Determinants of endoglin phosphorylation by transforming growth factor-beta receptors | Q79754253 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endothelium | Q111140 |
| | antibody | Q79460 |
| P304 | page(s) | e50920 | |
| P577 | publication date | 2012-12-27 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti-endoglin antibodies | |
| P478 | volume | 7 | |